论文部分内容阅读
目的比较吉西他滨单药或联合卡铂治疗老年晚期非小细胞肺癌(NSCLC)的临床疗效及1年生存率。方法老年晚期NSCLC患者40例随机分成两组:单用吉西他滨治疗组18例(单药组),吉西他滨加卡铂联合化疗组22例(联合组)。21 d为1个周期,每2个周期评价1次疗效。观察两组近期疗效、不良反应及1年生存率。结果单药组和联合组有效率分别为27.8%、40.9%;主要不良反应为骨髓抑制,两组差异无统计学意义,患者均可耐受;1年生存率联合组高于单药组(P<0.05)。结论吉西他滨联合卡铂治疗老年晚期NSCLC疗效优于单药治疗,耐受性好,可延长患者生存时间。
Objective To compare the clinical efficacy and 1-year survival rate of gemcitabine monotherapy or carboplatin in the treatment of advanced non-small cell lung cancer (NSCLC). Methods Forty elderly patients with advanced NSCLC were randomly divided into two groups: gemcitabine alone (18 cases) and gemcitabine plus carboplatin (22 cases). 21 d for a period of 1 evaluation every 2 cycles. The two groups were observed the short-term efficacy, adverse reactions and 1-year survival rate. Results The effective rates of single drug group and combined group were 27.8% and 40.9% respectively. The main adverse reactions were myelosuppression. There was no significant difference between the two groups, and the patients were tolerable. The 1-year survival rate was higher in the combination group than in the single drug group P <0.05). Conclusion Gemcitabine plus carboplatin is superior to monotherapy in the treatment of elderly patients with advanced non-small cell lung cancer (NSCLC). It is well tolerated and prolongs survival time.